Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Single-Blind, Dose-Rising Study to Evaluate the Safety, Tolerability and Preliminary Pharmacokinetics of Single and 14 Day Repeat Topical Applications of GSK1940029 Gel on the Intact Skin of Healthy Human Subjects

Trial Profile

A Randomized, Single-Blind, Dose-Rising Study to Evaluate the Safety, Tolerability and Preliminary Pharmacokinetics of Single and 14 Day Repeat Topical Applications of GSK1940029 Gel on the Intact Skin of Healthy Human Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 1940029 (Primary)
  • Indications Acne vulgaris
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 21 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
  • 25 Jul 2014 Planned End Date changed from 1 Feb 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.
  • 25 Jul 2014 Planned primary completion date changed from 1 Feb 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top